GT200800093A - Compuestos organicos - Google Patents

Compuestos organicos

Info

Publication number
GT200800093A
GT200800093A GT200800093A GT200800093A GT200800093A GT 200800093 A GT200800093 A GT 200800093A GT 200800093 A GT200800093 A GT 200800093A GT 200800093 A GT200800093 A GT 200800093A GT 200800093 A GT200800093 A GT 200800093A
Authority
GT
Guatemala
Prior art keywords
compounds
treatment
present
insulin
diabetes
Prior art date
Application number
GT200800093A
Other languages
English (en)
Inventor
Barnes David
Coppola Gary Mark
Stams Travis
Topiol Sidney Wolf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37903424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200800093(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200800093A publication Critical patent/GT200800093A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

SE PRESENTAN COMPUESTOS INHIBIDORES DE FOSFATASAS DE PROTEÌNA TIROSINA, PTPASAS, Y POR LO TANTO, SE PUEDEN EMPLEAR PARA EL TRATAMIENTO DE LAS CONDICIONES MEDIADAS POR LA ACTIVIDAD DE LA PTPASA. LOS COMPUESTOS DE LA PRESENTE INVENCIÒN TAMBIÈN SE PUEDEN EMPLEAR COMO INHIBIDORES DE OTRAS ENZIMAS CARACTERIZADAS POR UNA REGIÒN DE ENLACE DE FOSFOTIROSINA, TAL COMO EL DOMINIO SH2. DE ACUERDO CON LO ANTERIOR, LOS COMPUESTOS DE FÒRMULA (I) SE PUEDEN EMPLEAR PARA LA PREVENCIÒN Y/O TRATAMIENTO DE RESISTENCIA A LA INSULINA ASOCIADA CON OBSEIDAD, INTOLERANCIA A LA GLUCOSA, DIABETES MELLITUS, HIPERTENSIÒN Y ENFEREDADES ISQUÈMICAS DE LOS VASOS SANGUÌNEOS GRANDES Y PEQUEÑOS, CONDICIONES QUE ACOMPAÑAN A LA DIABETES TIPO 2, INCLUYENDO HIPERLIPIDEMIA, HIPERTRIGLICERIDEMIA, ATEROSCLEROSIS, RESTENOSIS VASCULAR, SÌNDROME DE INTESTINO IRRITABLE, PANCREATITIS, TUMORES DE CÈLULAS ADIPOSAS Y CARCINOMAS, TALES COMO LIPOSARCOMA, DISLIPIDEMIA Y OTROS TRASTORNOS EN DONDE SE INDIQUE LA RESISTENCIA A LA INSULINA. EN ADICIÒN, LOS COMPUESTOS DE LA PRESENTE INVENCIÓN SE PUEDEN EMPLEAR PARA TRATAR Y/O PREVENIR CÁNCER, OSTEOPOROSIS, ENFERMEDADES NEURODEGENERATIVAS E INFECCIOSAS, Y ENFERMEDADES QUE INVOLUCREN INFLAMACIÒN Y AL SISTEMA INMUNE. T2008
GT200800093A 2005-12-08 2008-06-06 Compuestos organicos GT200800093A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74849205P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
GT200800093A true GT200800093A (es) 2010-07-09

Family

ID=37903424

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800093A GT200800093A (es) 2005-12-08 2008-06-06 Compuestos organicos

Country Status (23)

Country Link
US (1) US8252820B2 (es)
EP (1) EP1963293A1 (es)
JP (1) JP2009518419A (es)
KR (1) KR20080075218A (es)
CN (1) CN101336235A (es)
AR (1) AR058285A1 (es)
AU (1) AU2006321902B2 (es)
BR (1) BRPI0619567A2 (es)
CA (1) CA2631007A1 (es)
CR (1) CR10047A (es)
EC (1) ECSP088509A (es)
GT (1) GT200800093A (es)
IL (1) IL191711A0 (es)
MA (1) MA30018B1 (es)
NO (1) NO20083030L (es)
NZ (1) NZ568663A (es)
PE (2) PE20100470A1 (es)
RU (1) RU2008127262A (es)
TN (1) TNSN08248A1 (es)
TW (1) TW200800928A (es)
UA (1) UA94921C2 (es)
WO (1) WO2007067612A1 (es)
ZA (1) ZA200804489B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1960377A1 (en) * 2005-12-08 2008-08-27 Novartis AG l , l , 3-TRI0X0-l , 2 , 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS
WO2007067613A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
MX2008012598A (es) * 2006-03-31 2008-10-10 Novartis Ag Tiadiazolidinonas inhibidoras de ptpasa.
DE102007015169A1 (de) * 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2012027134A1 (en) * 2010-08-26 2012-03-01 Albemarle Corporation Processes for producing 1-bromo-2 (cyclopropyl methoxy)-5 fluoro-4- methoxybenzene
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
AU2012248627A1 (en) 2011-04-28 2013-11-14 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2017078499A2 (ko) * 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
SG11202012820PA (en) * 2018-06-21 2021-01-28 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2020058009A1 (en) 2018-09-18 2020-03-26 Basf Se Diaminotriazine compounds
MA55301A (fr) * 2019-03-14 2022-01-19 Abbvie Inc Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
CN116348455A (zh) * 2019-12-18 2023-06-27 卡里科生命科学有限责任公司 蛋白质酪氨酸磷酸酶抑制剂和其使用方法
CA3162364A1 (en) * 2019-12-20 2021-06-24 Gesine Kerstin Veits Protein tyrosine phosphatase degraders and methods of use thereof
WO2022056281A1 (en) * 2020-09-11 2022-03-17 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
JP2024505192A (ja) 2021-01-27 2024-02-05 ビーエーエスエフ ソシエタス・ヨーロピア ジアミノトリアジン化合物
EP4305030A1 (en) * 2021-03-11 2024-01-17 Kumquat Biosciences Inc. Heterocycles and uses thereof
CA3236853A1 (en) * 2021-11-11 2023-05-19 Andrew Bogdan Protein tyrosine phosphatase inhibitors and methods of use thereof
CA3236854A1 (en) * 2021-11-11 2023-05-19 Andrew Bogdan Protein tyrosine phosphatase inhibitors and methods of use thereof
AR128379A1 (es) * 2022-01-31 2024-04-24 Bristol Myers Squibb Co Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
WO2023150535A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
TW202342437A (zh) * 2022-02-02 2023-11-01 美商耐瑞歐醫療公司 蛋白酪胺酸磷酸酶抑制劑及其用途
WO2023150150A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
WO2024059041A1 (en) * 2022-09-13 2024-03-21 Kumquat Biosciences, Inc. Benzo-fused n-heterocycles and uses thereof
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
WO2024102794A1 (en) * 2022-11-09 2024-05-16 Bristol-Myers Squibb Company Inhibitors of protein tyrosine phosphatase, compositions, and methods of use
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254342A1 (en) * 2001-03-23 2002-10-08 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
PT1492780E (pt) * 2002-04-03 2012-04-11 Novartis Ag Derivados 5-substituídos de 1,1-dioxo-1,2,5-tiazolidina-3- -ona como inibidores de ptpase 1b
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
GB0227813D0 (en) 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
WO2004062664A1 (en) * 2002-12-30 2004-07-29 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005035551A2 (en) * 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
EP1960377A1 (en) 2005-12-08 2008-08-27 Novartis AG l , l , 3-TRI0X0-l , 2 , 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS
WO2007067613A1 (en) 2005-12-08 2007-06-14 Novartis Ag 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
UA94724C2 (en) 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
MX2008012598A (es) 2006-03-31 2008-10-10 Novartis Ag Tiadiazolidinonas inhibidoras de ptpasa.

Also Published As

Publication number Publication date
UA94921C2 (en) 2011-06-25
NZ568663A (en) 2011-07-29
NO20083030L (no) 2008-08-28
AR058285A1 (es) 2008-01-30
BRPI0619567A2 (pt) 2011-10-04
US20100035942A1 (en) 2010-02-11
TW200800928A (en) 2008-01-01
CA2631007A1 (en) 2007-06-14
CN101336235A (zh) 2008-12-31
EP1963293A1 (en) 2008-09-03
US8252820B2 (en) 2012-08-28
AU2006321902A1 (en) 2007-06-14
PE20071094A1 (es) 2008-01-07
CR10047A (es) 2008-10-16
WO2007067612A1 (en) 2007-06-14
AU2006321902B2 (en) 2011-11-10
TNSN08248A1 (en) 2009-10-30
JP2009518419A (ja) 2009-05-07
RU2008127262A (ru) 2010-01-20
MA30018B1 (fr) 2008-12-01
IL191711A0 (en) 2008-12-29
ZA200804489B (en) 2009-08-26
PE20100470A1 (es) 2010-07-13
ECSP088509A (es) 2008-07-30
KR20080075218A (ko) 2008-08-14

Similar Documents

Publication Publication Date Title
GT200800093A (es) Compuestos organicos
ECSP088506A (es) Derivados de tiadiazol como agentes antidiabeticos
AR066820A1 (es) Compuestos de tiadiazolidin-3 ona
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
PA8840801A1 (es) Derivaos de dioxa-biciclo[3.2.1]octano-2,3,4-triol
WO2008127349A3 (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
EA200600414A1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
CL2012001043A1 (es) Compuestos derivados de hexahidroindenopiridina y/o octahidrobenzoquinolina, inhibidores de 11ß-hidroxiesteroide deshidrogenasa 1 (hsd 1); composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos para la preparacion de medicamentos para el tratamiento de trastornos metabolicos.
TW200602330A (en) Compounds and compositions as PPAR modulators
NO20076412L (no) Heterosykliske inhibitorer av mek og fremgangsmater for anvendelse derav
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
TW200612926A (en) Compounds and compositions as ppar modulators
WO2007089557A3 (en) Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
CL2011003079A1 (es) Compuestos derivados aromaticos o heteroaromaticos de heterociclos nitrogenados de oxima, agonista de receptor gpr119; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades mediadas por la modulacion de dicha actividad, como obecidad y diabetes.
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней